Immunocore and MedImmune, the global biologics R&D arm of AstraZeneca, have entered into a second collaboration to conduct combination trials in melanoma. Immunocore will conduct a Phase Ib/II trial combining MedImmune’s investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, its lead T-cell receptor, for the potential treatment of patients with metastatic melanoma. MedImmune has an exclusive relationship with Immunocore for the dev...